Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.47 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | GNPAT | O15228 | 1/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7047615 | 0.88 | GNPAT (0.56) | KMT2AFOLH1RIMKLANAALAD2CA2 | |
| SCHEMBL7231523 | 0.86 | NOD1 (0.39) | KMT2ACA2CA1ALOX15BLM | |
| SCHEMBL150160 | 0.85 | KMT2A (0.49) | KMT2AFOLH1RIMKLANAALAD2CA2 | |
| SCHEMBL27604132 | 0.85 | KMT2A (0.49) | KMT2AFOLH1RIMKLANAALAD2CA2 | |
| SCHEMBL7045847 | 0.85 | NOD1 (0.56) | KMT2AFOLH1RIMKLANAALAD2CA2 | |
| SCHEMBL4813214 | 0.85 | KMT2A (0.49) | KMT2AFOLH1RIMKLANAALAD2CA2 | |
| SCHEMBL31318372 | 0.85 | FOLH1 (0.52) | KMT2AFOLH1RIMKLANAALAD2CA2 | |
| SCHEMBL7046045 | 0.85 | NOD1 (0.60) | KMT2AFOLH1RIMKLANAALAD2CA2 | |
| SCHEMBL268801 | 0.85 | KMT2A (0.49) | KMT2AFOLH1RIMKLANAALAD2CA2 | |
| SCHEMBL4804865 | 0.84 | FOLH1 (0.67) | FOLH1RIMKLANAALAD2GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470678-B2 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | ASTRAZENECA AB (SE) | 2008-12-30 | — | — | US | disclosed |
| US-20050239766-A1 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | disclosed |
| EP-1521742-A1 | DIPHENYLAZETIDINONE DERIVATIVES FOR TREATING DISORDERS OF THE LIPID METABOLISM | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005247-A1 | DIPHENYLAZETIDINONE DERIVATIVES FOR TREATING DISORDERS OF THE LIPID METABOLISM | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239766-A1 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | CYP46A1, CYP27A1, CYP7A1 | KMT2A 3061/4885FOLH1 1455/4885RIMKLA 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.